“The comments received do not require any change to the conclusions of the NDA Panel.”
EFSA stands by CLA rejection
EFSA is standing by a CLA-weight loss health claim rejection despite an appeal that accused it of failing to evaluate submitted efficacy data from joint applicants BASF and Stepan Lipid Nutrition.